CJC-1295 + Ipamorelin Results: What Studies Measured and When
What published studies measured for CJC-1295 + Ipamorelin, when those outcomes were measured, and what is still unproven.
What studies measured
Each outcome below comes from a published study, with its type and size, strongest design first. Animal and cell results are labelled as such and are not human results. No study has tested CJC-1295 + Ipamorelin itself; the rows are for each ingredient.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Ipamorelin: Time to first tolerated meal | Median time to first tolerated meal was 25.3 h with ipamorelin and 32.6 h with placebo, a difference that was not statistically significant. | Human RCTn = 117 | International journal of colorectal disease 2014, PMID 25331030 |
| Ipamorelin: Overall efficacy | No significant difference from placebo in the key or secondary efficacy analyses. | Human RCTn = 117 | International journal of colorectal disease 2014, PMID 25331030 |
| CJC-1295: GH and IGF-I | A single injection raised mean plasma GH 2- to 10-fold for 6 days or more and mean IGF-I 1.5- to 3-fold for 9-11 days, dose-dependently. | Human RCT | The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 |
| CJC-1295: Repeat dosing | After multiple doses, mean IGF-I stayed above baseline for up to 28 days. | Human RCT | The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 |
| Ipamorelin: GH release | A single episode of GH release peaked at 0.67 hours and fell to negligible levels at all doses. | Human RCT | Pharmaceutical research 1999, PMID 10496658 |
| CJC-1295: Reasons for use reported on forums | Forum users cited weight loss, muscle enhancement, youthful skin, improved sleep and injury healing as reasons for use; these are user-stated motives, not measured results. | Human observational | Substance use & misuse 2016, PMID 26771670 |
| CJC-1295: Serum protein changes | CJC analog injection changed the intensity of five serum protein spots; these are candidate biomarkers of GH/IGF-1 action, not clinical outcomes. | Human uncontrolled trialn = 11 | Growth hormone & IGF research 2009, PMID 19386527 |
| CJC-1295: GH secretion pattern | Trough GH rose 7.5-fold, mean GH 46% and IGF-I 45% one week after a single injection, with GH pulsatility preserved. | Human uncontrolled trial | The Journal of clinical endocrinology and metabolism 2006, PMID 17018654 |
| CJC-1295: GH pulses | Frequency and magnitude of GH pulses were unchanged. | Human uncontrolled trial | The Journal of clinical endocrinology and metabolism 2006, PMID 17018654 |
| CJC-1295: Regulatory status and evidence for physique claims | The review notes no regulatory approval for physique- or performance-related indications of these peptides, including this long-acting GHRH analog. | Review | Frontiers in endocrinology 2026, PMID 42395176 |
| Ipamorelin: Regulatory status and evidence for physique claims | The review notes no regulatory approval for physique- or performance-related indications of these peptides, including ipamorelin. | Review | Frontiers in endocrinology 2026, PMID 42395176 |
| Ipamorelin: Cisplatin-induced weight loss | Ipamorelin did not change emesis but reduced cisplatin-induced weight loss by approximately 24% on the last day of the delayed phase (48-72 h). | Animal · ferret (not a human result) | Physiology & behavior 2024, PMID 39043357 |
| Ipamorelin: Visceral and somatic pain behaviour | Ipamorelin reduced colonic hypersensitivity and paw allodynia in rats; the models are not joint or back pain models. | Animal · rat (not a human result) | Journal of experimental pharmacology 2020, PMID 32801950 |
| Ipamorelin: Gastric emptying | After surgery 78% of the meal remained in the stomach in vehicle rats versus 52% with ipamorelin 0.014 umol/kg (44% in non-surgical controls). | Animal · rat (not a human result) | Journal of experimental pharmacology 2012, PMID 27186127 |
| Ipamorelin: Food intake and weight gain | Repeated dosing at 0.1 or 1 mg/kg increased fecal output, food intake and body weight gain in rats after surgery. | Animal · rat (not a human result) | The Journal of pharmacology and experimental therapeutics 2009, PMID 19289567 |
| CJC-1295: Growth and body composition | Once-daily CJC-1295 maintained normal growth and body composition in GHRH knockout mice. | Animal · mouse (not a human result) | American journal of physiology. Endocrinology and metabolism 2006, PMID 16822960 |
| CJC-1295: Dosing interval | The same dose was less effective given every 48 or 72 h. | Animal · mouse (not a human result) | American journal of physiology. Endocrinology and metabolism 2006, PMID 16822960 |
| CJC-1295: GH release | CJC-1295 produced a 4-fold larger 2-h GH area under the curve than hGRF(1-29) in rats. | Animal · rat (not a human result) | Endocrinology 2005, PMID 15817669 |
| Ipamorelin: Muscle strength and bone formation under glucocorticoid | Adding ipamorelin to glucocorticoid increased calf-muscle tetanic tension and raised periosteal bone formation four-fold versus glucocorticoid alone. | Animal · rat (not a human result) | Growth hormone & IGF research 2001, PMID 11735244 |
| Ipamorelin: Body weight and bone mineral content | Ipamorelin, another GHRP and GH all increased body weight and bone mineral content versus vehicle; BMC per body weight was unchanged. | Animal · rat (not a human result) | The Journal of endocrinology 2000, PMID 10828840 |
| Ipamorelin: Bone growth and body weight | Longitudinal bone growth rose dose-dependently from 42 microm/day (vehicle) to 44, 50 and 52 microm/day, with dose-dependent body weight gain. | Animal · rat (not a human result) | Growth hormone & IGF research 1999, PMID 10373343 |
| Ipamorelin: Selectivity for GH release | Ipamorelin released GH with selectivity similar to GHRH in these preclinical models. | Animal · rat and swine (plus rat pituitary cells in vitro) (not a human result) | European journal of endocrinology 1998, PMID 9849822 |
| Ipamorelin: ACTH and cortisol | Unlike other GHRP agonists, ipamorelin did not raise ACTH or cortisol beyond GHRH-stimulated levels in swine. | Animal · rat and swine (plus rat pituitary cells in vitro) (not a human result) | European journal of endocrinology 1998, PMID 9849822 |
| Ipamorelin: Clearance and nasal absorption | Intranasal bioavailability of ipamorelin in rats was approximately 20%. | Animal · rat (not a human result) | Xenobiotica; the fate of foreign compounds in biological systems 1998, PMID 9879640 |
- CJC-1295: Human data: two randomized placebo-controlled dose-escalation trials in healthy adults (16352683, which reports pharmacokinetics and safety), one uncontrolled study of GH pulsatility in 20-40 year old men (17018654) and a proteomic study in 11 men (19386527). All used the albumin-binding (DAC) form; CJC-1295 without DAC (sometimes sold as modified GRF 1-29) is not covered by this literature.
- CJC-1295: All human studies are in healthy adults and measured GH and IGF-I, not weight, muscle, sleep or energy outcomes. No human study measuring weight loss, muscle growth, sleep, energy or bodybuilding outcomes was found in PubMed as of 2 October 2026. Women over 50 and men over 50 have no age-specific data (participants were 21-61).
- CJC-1295: The sleep and weight-loss goals have no efficacy evidence; one study (26771670) only records why forum users say they use the peptide.
- CJC-1295: CJC-1295 is not an approved drug and there is no FDA label. No stability data were found.
- Ipamorelin: Human evidence is limited to two studies: a phase 2 randomized trial in 117 bowel-resection patients (25331030) that found no significant benefit over placebo for time to first tolerated meal, and a pharmacokinetic/pharmacodynamic study in healthy male volunteers (10496658). No human trial of ipamorelin for the listed lifestyle goals has been published in PubMed as of 2 October 2026.
- Ipamorelin: No human study found for: energy, sleep, joint pain, arthritis, rheumatoid arthritis, back pain, menopause or perimenopause, longevity, belly fat, blood pressure, cholesterol, heart health, bulking, cutting, or age-specific goals (men and women over 40 or 50).
- Ipamorelin: Everything else is animal work (rat, swine, ferret) or pharmacology. The pain study (32801950) used visceral and paw hypersensitivity models, not joint or back pain. Body-weight and bone findings in rats do not show effects in people.
- Ipamorelin: Ipamorelin is not an approved drug and has no FDA label. No stability study was found.
Typical timeline
When the studies above measured their outcomes. This is the study schedule, not a promise of when anyone will notice a change.
| When | What was measured | Study type | Source |
|---|---|---|---|
| 6 d or more (GH); 9-11 d (IGF-I) | CJC-1295: Duration of GH and IGF-I elevation after one injection | Human RCT | The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 |
| 1 wk after injection | CJC-1295: GH pulsatility and IGF-I | Human uncontrolled trial | The Journal of clinical endocrinology and metabolism 2006, PMID 17018654 |
Before-and-after photos
We don't publish before-and-after photos. They can't be verified, rarely show dose, diet or other drugs, and only the most dramatic results get posted.
Common questions
How long does CJC-1295 + Ipamorelin take to work?
The studies we summarise measured outcomes at set points, for example Duration of GH and IGF-I elevation after one injection at 6 d or more (GH); 9-11 d (IGF-I); GH pulsatility and IGF-I at 1 wk after injection. Timelines outside studies vary.
Do you show CJC-1295 + Ipamorelin before and after photos?
No. Photos can't be verified, rarely show dose, diet or other drugs, and only the most dramatic ones get posted. We summarize measured outcomes instead.
More on CJC-1295 + Ipamorelin
DosageDoses used in published studies, with the source for each.Blend calculatorSplit a blend vial into per-peptide amounts and units.Side effectsWhat labels and studies report, and what is unknown.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.
Sources
- 1Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 2Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 3Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 4Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.Substance use & misuse · 2016PMID 26771670Accessed 2 Oct 2026
- 5Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009PMID 19386527Accessed 2 Oct 2026
- 6Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
- 7The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
- 8The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
- 9Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.Journal of experimental pharmacology · 2020PMID 32801950Accessed 2 Oct 2026
- 10Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.Journal of experimental pharmacology · 2012PMID 27186127Accessed 2 Oct 2026
- 11Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.The Journal of pharmacology and experimental therapeutics · 2009PMID 19289567Accessed 2 Oct 2026
- 12Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
- 13Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.Endocrinology · 2005PMID 15817669Accessed 2 Oct 2026
- 14The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2001PMID 11735244Accessed 2 Oct 2026
- 15The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.The Journal of endocrinology · 2000PMID 10828840Accessed 2 Oct 2026
- 16Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 1999PMID 10373343Accessed 2 Oct 2026
- 17Ipamorelin, the first selective growth hormone secretagogue.European journal of endocrinology · 1998PMID 9849822Accessed 2 Oct 2026
- 18Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.Xenobiotica; the fate of foreign compounds in biological systems · 1998PMID 9879640Accessed 2 Oct 2026
Found an error? Report a correction.